The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.

OBJECTIVE It has been suggested that subchondral bone remodeling plays a role in the progression of osteoarthritis (OA). To test this hypothesis, we characterized the changes in the rat anterior cruciate ligament transection (ACLT) model of OA and evaluated the effects of alendronate (ALN), a potent inhibitor of bone resorption, on cartilage degradation and on osteophyte formation. METHODS Male Sprague-Dawley rats underwent ACLT or sham operation of the right knee. Animals were then treated with ALN (0.03 and 0.24 microg/kg/week subcutaneously) and necropsied at 2 or 10 weeks postsurgery. OA changes were evaluated. Subchondral bone volume and osteophyte area were measured by histomorphometric analysis. Coimmunostaining for transforming growth factor beta (TGF beta), matrix metalloproteinase 9 (MMP-9), and MMP-13 was performed to investigate the effect of ALN on local activation of TGF beta. RESULTS ALN was chondroprotective at both dosages, as determined by histologic criteria and collagen degradation markers. ALN suppressed subchondral bone resorption, which was markedly increased 2 weeks postsurgery, and prevented the subsequent increase in bone formation 10 weeks postsurgery, in the untreated tibial plateau of ACLT joints. Furthermore, ALN reduced the incidence and area of osteophytes in a dose-dependent manner. ALN also inhibited vascular invasion into the calcified cartilage in rats with OA and blocked osteoclast recruitment to subchondral bone and osteophytes. ALN treatment reduced the local release of active TGF beta, possibly via inhibition of MMP-13 expression in articular cartilage and MMP-9 expression in subchondral bone. CONCLUSION Subchondral bone remodeling plays an important role in the pathogenesis of OA. ALN or other inhibitors of bone resorption could potentially be used as disease-modifying agents in the treatment of OA.

[1]  A. Ratcliffe,et al.  Biochemical markers of osteoarthritis. , 1990, Current opinion in rheumatology.

[2]  K. Brandt,et al.  Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. , 1999, The Journal of rheumatology.

[3]  D. Burr,et al.  The importance of subchondral bone in osteoarthrosis. , 1998, Current opinion in rheumatology.

[4]  C. Leu,et al.  The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. , 1998, Endocrinology.

[5]  P. Ross,et al.  Evidence that increased calcium intake does not prevent early postmenopausal bone loss. , 1998, Clinical therapeutics.

[6]  K. Pavelka,et al.  Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. , 2002, Osteoarthritis and cartilage.

[7]  R. Read,et al.  Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). , 2000, Osteoarthritis and cartilage.

[8]  C. P. Leblond,et al.  Enzymes active in the areas undergoing cartilage resorption during the development of the secondary ossification center in the tibiae of rats aged 0–21 days. II. Two proteinases, gelatinase B and collagenase‐3, are implicated in the lysis of collagen fibrils , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[9]  K. O'Connor.  Unweighting Accelerates Tidemark Advancement in Articular Cartilage at the Knee Joint of Rats , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  D. Rimoin,et al.  Alkaline and acid phosphatase demonstration in human bone and cartilage: effects of fixation interval and methacrylate embedments. , 1988, Stain technology.

[11]  S. Carter,et al.  Serum level of cartilage oligomeric matrix protein (COMP) in equine osteoarthritis. , 2010, Equine veterinary journal.

[12]  E. Märker-Hermann,et al.  Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. , 1996, Clinical and experimental rheumatology.

[13]  Mark E. Bolander,et al.  Regulation of Fracture Repair by Growth Factors , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[14]  E. Thonar,et al.  Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. , 1999, Arthritis and rheumatism.

[15]  P. Billings,et al.  Activation of Transforming Growth Factor β in Chondrocytes Undergoing Endochondral Ossification , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  P Young,et al.  Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. , 1993, Annals of the rheumatic diseases.

[17]  R. Mason,et al.  The STR/ort mouse and its use as a model of osteoarthritis. , 2001, Osteoarthritis and cartilage.

[18]  M. Seibel,et al.  Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. , 1989, The Journal of rheumatology.

[19]  G. Rodan,et al.  Preclinical pharmacology of alendronate , 2005, Osteoporosis International.

[20]  E. Orwoll.  Osteoporosis in men. , 1998, Endocrinology and metabolism clinics of North America.

[21]  P. Delmas,et al.  The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. , 2001, Bone.

[22]  D. Hurwitz,et al.  Bone mineral density varies as a function of the rate of joint space narrowing in the hip. , 2000, The Journal of rheumatology.

[23]  M. Stearns,et al.  Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice , 1998, Clinical & Experimental Metastasis.

[24]  L. Devy,et al.  Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.

[25]  D. Bauer.  Osteoporotic fractures: ignorance is bliss? , 2000, American Journal of Medicine.

[26]  L. Duong,et al.  Expression of the cartilage derived anti-angiogenic factor chondromodulin-I decreases in the early stage of experimental osteoarthritis. , 2003, The Journal of rheumatology.

[27]  C. Little,et al.  Histomorphological and immunohistochemical evaluation of joint changes in a model of osteoarthritis induced by lateral meniscectomy in sheep. , 1997, The Journal of rheumatology.

[28]  K. Brandt,et al.  Bone scintigraphy in the canine cruciate deficiency model of osteoarthritis. Comparison of the unstable and contralateral knee. , 1997, The Journal of rheumatology.

[29]  Y. Iwamoto,et al.  Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis , 2000, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[30]  R. Kandel,et al.  Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. , 1999, The Journal of rheumatology.

[31]  Gideon A. Rodan,et al.  Control of osteoblast function and regulation of bone mass , 2003, Nature.

[32]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[33]  D. Heymann,et al.  Recent advances in TGF-β effects on chondrocyte metabolism , 2002 .

[34]  D. Burr,et al.  The involvement of subchondral mineralized tissues in osteoarthrosis: Quantitative microscopic evidence , 1997, Microscopy research and technique.

[35]  J. Puzas,et al.  Transforming growth factor beta: an autocrine regulator of chondrocytes. , 1989, Connective tissue research.

[36]  J. Santibañez,et al.  Transforming growth factor-b1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes , 2002 .

[37]  J. Seedor,et al.  The bisphosphonate alendronate (MK‐217) inhibits bone loss due to ovariectomy in rats , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  K. Kippo,et al.  Effect of clodronate on established collagen-induced arthritis in rats , 1995, Inflammation Research.

[39]  A. Yamaguchi,et al.  Acid phosphatase activity is detected preferentially in the osteoclastic lineage by pre-treatment with cyanuric chloride. , 1991, Journal of Histochemistry and Cytochemistry.

[40]  Freddie H. Fu,et al.  Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee , 2005, Knee Surgery, Sports Traumatology, Arthroscopy.

[41]  E. Thonar,et al.  The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. , 2002, Osteoarthritis and cartilage.

[42]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[43]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  S. Goldstein,et al.  A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. , 1993, Arthritis and rheumatism.

[45]  T. Salo,et al.  Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines , 2002, Anti-cancer drugs.

[46]  R. Derynck,et al.  Osteoblastic Responses to TGF-β during Bone Remodeling , 1998 .

[47]  F. Emmrich,et al.  Treatment of rat arthritides with clodronate-containing liposomes. , 1995, Scandinavian journal of rheumatology. Supplement.

[48]  R. Maki,et al.  References Subscriptions Permissions Email Alerts Expression and Regulation of Aggrecanase in Arthritis: The Role of TGF- β , 2013 .

[49]  Alain Buisson,et al.  A Soluble Transforming Growth Factor-β (TGF-β) Type I Receptor Mimics TGF-β Responses* , 2001, The Journal of Biological Chemistry.

[50]  A. Lombardi.  Treatment of Paget's disease of bone with alendronate. , 1999, Bone.

[51]  T. Salo,et al.  MMP Inhibition and Downregulation by Bisphosphonates , 1999, Annals of the New York Academy of Sciences.

[52]  D. Heinegård,et al.  Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.

[53]  L. Klareskog,et al.  Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. , 1997, British journal of rheumatology.

[54]  Lynn Wei,et al.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. , 1997, The Journal of clinical investigation.

[55]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[56]  C. Christiansen,et al.  Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products , 2002, Annals of the rheumatic diseases.

[57]  Lynda F. Bonewald,et al.  Proteolysis of Latent Transforming Growth Factor-β (TGF-β)-binding Protein-1 by Osteoclasts , 2002, The Journal of Biological Chemistry.

[58]  Jiahuai Han,et al.  Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. , 2002, The Journal of biological chemistry.

[59]  S. Goldstein,et al.  Early bone changes in experimental osteoarthritis using microscopic computed tomography. , 1991, The Journal of rheumatology. Supplement.

[60]  W. Hayes,et al.  Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone. , 1996, The Journal of pharmacology and experimental therapeutics.

[61]  R. Rose,et al.  Role of Subchondral Bone in the Initiation and Progression of Cartilage Damage , 1986, Clinical orthopaedics and related research.

[62]  A. Oberbauer,et al.  Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. , 2003, Bone.

[63]  C. Helmick,et al.  Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. , 2002, Osteoarthritis and cartilage.

[64]  P. Sime,et al.  Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. , 2001, Osteoarthritis and cartilage.

[65]  S. Breusch,et al.  Ultrastructural findings after intraarticular application of hyaluronan in a canine model of arthropathy , 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[66]  M. Nevitt,et al.  Osteoarthritis, bone mass, and fractures: how are they related? , 2002, Arthritis & Rheumatism.

[67]  K. Abendroth,et al.  Osteoarthritis and bone: osteologic types of osteoarthritis of the hip , 1989, Skeletal radiology.

[68]  Alain Buisson,et al.  A soluble TGF-beta type-1 receptor mimics TGF-beta responses , 2001 .

[69]  A J Bailey,et al.  Biochemical evidence for altered subchondral bone collagen metabolism in osteoarthritis of the hip. , 1997, British journal of rheumatology.